Securities Analyst Recommendations: Akoustis Technologies, Inc. (AKTS), Can-Fite BioPharma Ltd. (CANF)

Akoustis Technologies, Inc. (NASDAQ:AKTS) tinted loss of -1.78% (-0.13 points) to US$7.16. The volume of 0.11 Million shares climbed down over an trading activity of 203.44 Million shares. EPS ratio determined by looking at last 12 month figures is -1.09. Over the same time span, the stock marked US$9.5 as its best level and the lowest price reached was US$3.4. The corporation has a market cap of US$206.28 Million.

Akoustis Technologies, Inc. (NASDAQ:AKTS)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -134.3 percent while most common profitability ratio return on investment (ROI) was -88.1 percent. The company’s institutional ownership is monitored at 17.3 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 8.1 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 1 think it is Hold. Recently, analysts have updated the overall rating to 1.86. 4 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Can-Fite BioPharma Ltd. (NYSE:CANF) is worth US$51.13 Million and has recently risen 0.86% to US$1.17. The latest exchange of 0.15 Million shares is below its average trading activity of 190.91 Million shares. The day began at US$1.16 but the price moved to US$1.16 at one point during the trading and finally capitulating to a session high of US$1.16. The stock tapped a 52-week high of US$2.25 while the mean 12-month price target for the shares is US$8.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 4.01, and a price to sales ratio of 14.14. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 23.39%, it carries an earnings per share ratio of -0.26.